Given the intrinsic link between the Keap1/Nrf2 pathway and metastatic possibility, it is likely that metastatic tumors harboring Keap1/Nrf2 mutations in HN-CSCs may pose multiple risks of distant metastatic disease. This evidence concerns the gene KEAP1 and metastatic neoplasm.